TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Histologically confirmed unresectable Stage III or IV melanoma~* Treatment-naive or experienced disease recurrence or progression during or after one prior systemic regimen for advanced disease~* Measurable disease by Computed Tomography/Magnetic resonance imaging (CT/MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Known BRAF V600 mutation status or consent to BRAF V600 mutation testing~* Sufficient tumor tissue accessible for baseline and post-treatment biopsies.~Exclusion Criteria:~* Active central nervous system (CNS) metastases~* Carcinomatous meningitis~* Active, known or suspected autoimmune disease~* Condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization~* Prior therapy with anti-Programmed Death-1 (PD1), anti-Programmed Death-Ligand 1 (PD-L1), anti-PD-L2, anti-CD137, or anti-CTLA-4 (cytotoxic T lymphocyte antigen 4) antibody~* Prior treatment with other immunotherapies~* Prior therapy with BRAF inhibitor within 6 weeks of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A: Nivolumab followed by Ipilimumab (Type: EXPERIMENTAL): Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1.~Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period.
- Cohort B: Ipilimumab followed by Nivolumab (Type: EXPERIMENTAL): Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period.~Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject, of any race, who is at least 1 year of age.~* Subjects must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit mucopurulent or purulent conjunctival discharge (crusty or sticky eyelids, globular and yellow discharge) and redness in at least one eye.~* The symptoms of bacterial conjunctivitis must be present for 3 days (approximately 72 hours) or less.~* Must be willing to discontinue contact lens wear for the duration of the study.~Exclusion Criteria:~* Any uncontrolled systemic disease or debilitating disease.~* Use of topical ophthalmic solutions including tear substitutes within 2 hours before and during the study.~* Use of any topical ophthalmic anti-inflammatory agents within 48 hours before and during study.~* Any active upper respiratory tract infection.~* Pregnant or nursing females.~* Use of any antibiotic (topical or systemic) within 72 hours of enrollment.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AzaSite (Type: EXPERIMENTAL): 1.0% azithromycin in DuraSite
- Tobramycin (Type: ACTIVE_COMPARATOR): 0.3% tobramycin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Treatment of Root Caries in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60 + years old~* community-dwelling~* living in a community with fluoridated water~* had five or more of their own teeth~* with ≥ 1 root caries lesion~Exclusion Criteria:~* cognitive impairment~* alcoholism

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- High Fluoride Toothpaste (Type: EXPERIMENTAL): 5,000 ppm fluoridated toothpaste, high concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
- Standard Fluoride Toothpaste (Type: ACTIVE_COMPARATOR): 1,450 ppm fluoridated toothpaste, low concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All subjects to be entered must:~* be at least 18 years of age.~* if female, be nonpregnant as evidenced by a serum pregnancy test and using a medically-approved method of birth control, or post-menopausal or surgically sterile~* provide written informed consent after having received oral and written information about the study~* be in stable health based on medical history, examination and tests~Exclusion Criteria:~have a positive pregnancy test (females)~* received an investigational drug or device within 30 days prior to administration of SeeMore~* have known hypersensitivity to ondansetron or other selective serotonin 5HT3 receptor blockers~* have a history of drug abuse or alcoholism~* are taking a digitalis preparation or calcium channel blocker~* have a history of torsades or prolonged QT/QTc interval~* have NYHA Grade IV heart failure~* have abnormal liver function tests or a history of liver disease~* have uncontrolled hypertension (Systolic Blood Pressure \> 140 or Diastolic BP \> 90 consistently at baseline)~* have abnormal baseline potassium or calcium values or hemoglobin less than 10 g/dl~* are noncompliant or otherwise unlikely to perform as required by the protocol~* have pretest likelihood of CAD for which the requisite number of subjects have been entered~* develop an arrhythmia prior to or during either of the exercise tests; SeeMore should not be administered.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Coronary Disease (Type: EXPERIMENTAL): Participant receive 2 cardiac MRI procedures: MEMRI and DEMRI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older~* Tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic therapy and for which no standard therapy exists~* Expansion cohort only: Advanced lymphoma confirmed by histopathology~* Measurable or evaluable disease according to RECIST for solid tumors or according to IWRC for NHL tumors~* ECOG Performance Status less than or equal to 2~* Life expectancy greater than 12 weeks in the opinion of the Investigator~Exclusion Criteria:~* Any active or uncontrolled infection~* NYHA Grade II or greater congestive heart failure~* History of myocardial infarction within 6 months prior to screening~* Prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy within 4 weeks prior to screening or 5 half-lives of the therapy, whichever is shorter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): IONIS-STAT3Rx

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic atrial flutter requiring radiofrequency ablation.~* Chronic atrial fibrillation requiring internal cardioversion.~Exclusion Criteria:~* Sinus rhythm.~* Pregnancy.~* Patients \> 80 years and \< 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): No fish oil
- Fish oil (Type: EXPERIMENTAL): Patients prescribed 6g/day of fish oil containing 1.8g EPA+DHA in a 1.5:1 ratio

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adenotonsillectomy for Obstructive Sleep-Disordered Breathing in Childhood:The Chania Community Oximetry-Based Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with obstructive SDB (snoring \>3 nights/week over the last 6 months)~* Tonsillar size \>2 \[Brodsky 1989\]~* Considered as an AT candidate during the clinic visit by ear, nose and throat (ENT) surgeon~Exclusion Criteria:~* Recurrent tonsillitis defined as at least 3 episodes in each of the last 3 years or at least 5 episodes in each of the last 2 years or at least 7 episodes in the past year.~* Apparent craniofacial anomalies (e.g. Crouzon syndrome or Pierre-Robin sequence)~* Obstructive breathing while awake or any other clinical signs that merit prompt AT as recommended by the treating ENT physician.~* History of clinically important cardiovascular disease or cardiac arrhythmia.~* History of: sickle cell disease; symptomatic asthma; epilepsy; use of sedative medication~* History of: genetic disorders; neurological or neuromuscular disorders~* Use of: systemic or intranasal corticosteroids; montelukast~Footnote~Brodsky score Upon inspection of the oropharynx~* grade 1 indicates that the tonsils are hidden in the pillars~* grade 2 indicates that the tonsils are beyond the anterior pillar and occupy between 25 and 50% of the pharyngeal space~* grade 3 indicates that the tonsils are beyond the pillars but not to the middle and occupy \>50% and up to 75% of the pharyngeal space~* grade 4 indicates that the tonsils occupy \>75% of the pharyngeal space

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- AT (adenotonsillectomy) Group (Type: ACTIVE_COMPARATOR): AT (adenotonsillectomy) immediately after the baseline study evaluation
- Control Group (Type: NO_INTERVENTION): No AT (adenotonsillectomy) for 3 months after the baseline study evaluation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trigeminal Nerve Stimulation for ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male and female children ages 8 to 12 years with DSM-5 ADHD, any current presentation, as determined by KSADS and clinical interview~* minimum scores of 12 on both the inattentive and hyperactive/impulsive subscales of the baseline ADHD-RS~* CGI-S score at baseline ≥ 4~* no current medication with CNS effects~* parents able and willing to monitor proper use of the stimulation device and complete all required rating scales~* estimated Full Scale IQ ≥ 85 based on WASI subtests~* parent and participant able to complete rating scales and other measures in English~* able to cooperate during EEG~Exclusion Criteria:~* impaired functioning to a degree that requires immediate initiation of ADHD medication in the opinion of the parents and/or investigator~* current diagnosis of autism spectrum disorder or major depression~* history of lifetime psychosis, mania, seizure disorder or head injury with loss of consciousness~* baseline suicidality

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Active eTNS (Type: EXPERIMENTAL): Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
- Sham eTNS (Type: SHAM_COMPARATOR): Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HbA1c between 7.5% - 10%~* On diet \& exercise, metformin (MET), sulfonylurea (SU) or thiazolidinedione (TZD) alone or in combination or combined (SU + TZD) or in combination with Met + SU, Met + TZD, Met + TZD + SU~* BMI between 25 \& 45 kg/m2~Exclusion Criteria:~* taking DPP-4 inhibitors, exenatide, liraglutide, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months~* history of pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ITCA 650 40 mcg/day (Type: EXPERIMENTAL): None
- ITCA 650 60 mcg/day (Type: EXPERIMENTAL): None
- ITCA placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Cancer patients treated with anthracycline~2. Informed consent obtained from the patient.~3. Suspicion of anthracycline extravasation is defined as:~   A primary assessment by the physician on duty, which would activate the standard departmental procedure for treatment of anthracycline extravasation.~   The presence of at least one of the following:~  * pain~  * swelling~  * redness~4. The Topotect infusion must be started \<6 hours after the accident.~5. The patient must be at least 18 years of age.~6. Performance status (PS) ≤2.~7. Suspicion of anthracycline extravasation from a central venous access device. -~Exclusion Criteria:~1. Known allergy towards dexrazoxane.~2. Reasonable suspicion of extravasation by other compounds than anthracyclines through the same intravenous access, e.g. vincristine, mitomycin, and vinorelbine, all of which may cause ulceration.~3. AST, ALT, bilirubin, LDH, serum alkaline phosphatase \>3 x upper normal value~4. Neutropenia and thrombocytopenia ≥ CTC grade 2~5. Pregnant or nursing women~6. Women of childbearing age and potential, where the patient does not agree to use an efficient contraceptive (e.g. birth control pill or an intra-uterine device for 3 months previous to start of the trial medication or diaphragm plus a spermicide).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Supporting Family Caregivers With Technology for Dementia Home Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Person caring for someone with a diagnosis of Alzheimer's disease or other dementia at home.~Exclusion Criteria:~* Exclusion criteria include Huntington's disease, alcohol-related dementia, schizophrenia, manic-depressive disorder, deafness, and mental retardation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention FamTechCare (Type: EXPERIMENTAL): This group will submit videos and receive weekly feed back after review by dementia care experts for managing challenging care situations. The intervention is weekly individualized feedback based on video data (FamTechCare).
- Control and Delayed FamTechCare (Type: PLACEBO_COMPARATOR): This group will submit videos and will receive weekly feedback from a nurse based on their verbal communication until the end of their participation. At the end of the study, they will receive feedback based on submitted videos from dementia care experts (delayed FamTechCare).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Preoperative N1539 in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily provide written informed consent.~* Be planned to undergo an elective, primary (no repeat arthroplasties) open unilateral total knee arthroplasty (TKA), and be expected to require IV analgesia, remain in an inpatient setting for ≥24 hours, and receive at least two doses of study drug.~* ASA physical status category 1, 2, or 3.~* Female subjects not pregnant or planning/attempting to become pregnant, not lactating; or commits to the use of an acceptable form of birth control for the duration of the study.~* Have a body mass index \<40 kg/m\^2~Exclusion Criteria:~* Have a known allergy or hypersensitivity to any study treatment.~* Have a history of previous TKA.~* Has plans for a concurrent surgical procedure (eg, bilateral TKA).~* Has TKA planned to be performed under general anesthesia.~* Have a history of myocardial infarction within the preceding 12 months.~* Have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant condition that would preclude participation.~* Have active or recent (within 6 months) gastrointestinal ulceration or bleeding.~* Have a known bleeding disorder which may be worsened with the administration of an NSAID.~* Be currently receiving treatment with oral meloxicam (Mobic®) or another NSAID within 48 hours prior to surgery.~* Have previously received N1539/IV meloxicam or received any investigational product within 30 days before dosing with study medication.~* Have undergone or be expected to undergo radiation therapy, chemotherapy, or other biological therapy for cancer treatment, within 60 days prior to screening through last follow-up.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- N1539 30 mg (Type: EXPERIMENTAL): N1539 (meloxicam injection for IV use) 30 mg every 24 hours
- IV Placebo (Type: PLACEBO_COMPARATOR): IV Placebo every 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Analgesia After Interscalene Block After Arthroscopic Shoulder Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Dutch or English speaking adults~* 18 years or older ASA I-III physical class~* Scheduled for elective arthroscopic shoulder surgery~Exclusion Criteria:~* History of allergy to a local anesthetic~* Baseline neurological deficit~* Medical condition that would make it difficult to assess sensory distribution or communicate with the investigators' staff~* Recent history (\< 3 months) of drug or alcohol abuse~* Concomitant opioid therapy~* Preexisting coagulation disorder~* Infection at the injection site~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Exparel block in arthroscopic surgery (Type: EXPERIMENTAL): Evaluation of Exparel block in arthroscopic shoulder surgery.
- Bupivacaine block in shoulder surgery (Type: EXPERIMENTAL): Evaluation of Bupivacaine block in shoulder surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete